We use own cookies and thirds to offer you better service More information Accept
Back to News

May. 2018

Qualigen launches Rosuvastatin


Qualigen launches Rosuvastatin to treat high cholesterol and to prevent cardiovascular disease

26th April 2018. Qualigen launches Rosuvastatina 5 mg, 10 mg and 20 mg film-coated tablets EFG.

Rosuvastatina Qualigen EFG is bioequivalent to Crestor® and is indicated to treat high cholesterol and to prevent cardiovascular disease

Rosuvastatine Qualigen is marketed in presentations of 28 tablets of 5 mg, 10 mg and 20 mg.

Rosuvastatine Qualigen requires a prescription for dispensing and is financed by the Spanish Health System with reduced contribution.

With this launch, Qualigen extends its product portfolio of drugs to prevent cardiovascular disease.